Fig. 3

Recombinant Angptl4 stimulates the proliferation of myeloid CFUs in vitro and expands myeloid progenitors in vivo. a CFU activity of 3 × 10⁴ murine BM cells per well in the presence of SCF, TPO, and Flt3L. Addition of Angptl4, G-CSF, GM-CSF, and IL-3 as indicated. b CFU numbers per 3 × 10⁴ seeded BM cells of the PBS-treated (white bars) or Angptl4-treated (gray bars) WT mice in the presence of the following cytokines: IL-3, IL-6, SCF, GM-CSF, TPO, and EPO. Mice were daily injected with 250 μg/kg murine Angptl4 per kg body weight for five consecutive days. Mice were analyzed 48 h after the last injection. Mean ± SEM of two different experiments with a total of six PBS-injected and six Angptl4-injected mice are shown. c Representative FACS profiles of Lin⁻ BM cells from the PBS- and Angptl4-injected WT mice. Lin⁻ c-Kit^high Sca-1⁻ cells were subdivided into three subsets based on FcγRII/III and CD34 expression: CD34⁺FcγRII/III⁻ (CMP), CD34⁺FcγRII/III⁺ (granulocyte/monocyte progenitors; GMP), and CD34⁻FcγRII/III⁻ (MEP). Numbers indicate percentages of total BM cells and fold changes of CD34⁺FcγRII/III⁺ fractions in the PBS- vs. Angptl4-treated mice are shown. d GMP frequency as percentage of total cells, as well as total cell numbers in PBS- vs. Angptl-injected mice, treated as in b. Mean ± SEM of three different experiments with three PBS-injected and three Angptl4-injected mice/group are shown. Statistically significant differences are indicated (*p < 0.05, ***p < 0.001)